Cogent Biosciences, Inc. (COGT) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cogent Biosciences, Inc. (COGT) Earnings Overview
As of June 28, 2026, Cogent Biosciences, Inc. (COGT) reported trailing twelve-month net income of -$354M, reflecting -3.7% year-over-year growth. The company earned $-5.26 per diluted share over the past four quarters.
Looking at the long-term picture, COGT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2015.
Cogent Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), MRUS (-$335M net income, -595.9% margin), PRAX (-$327M net income), COGT has comparable earnings metrics. Compare COGT vs KYMR →
COGT Earnings vs Peers
Earnings metrics vs comparable public companies
COGT Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$329M | -28.6% | -$333M | $-2.55 | - | - |
| 2024 | -$256M | -33.0% | -$276M | $-2.46 | - | - |
| 2023 | -$192M | -37.2% | -$208M | $-2.42 | - | - |
| 2022 | -$140M | -94.0% | -$148M | $-2.26 | - | - |
| 2021 | -$72M | +3.4% | -$76M | $-1.85 | - | - |
| 2020 | -$75M | -147.1% | -$82M | $-6.00 | -950.4% | -1044.3% |
| 2019 | -$30M | +12.3% | -$32M | $-3.97 | -134.6% | -143.0% |
| 2018 | -$35M | -35.5% | -$36M | $-5.55 | -354.8% | -369.9% |
| 2017 | -$25M | -40.7% | -$26M | $-3.45 | -304.9% | -312.8% |
| 2016 | -$18M | -174.9% | -$19M | $-2.45 | -285.2% | -300.1% |
| 2015 | -$7M | - | -$7M | $-0.89 | -220.8% | -220.8% |
Download Data
Export COGT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
COGT — Frequently Asked Questions
Quick answers to the most common questions about buying COGT stock.
What is COGT earnings per share (EPS)?
COGT trailing twelve-month (TTM) diluted EPS is $-5.26, reflecting -3.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Cogent Biosciences, Inc.'s net income?
Cogent Biosciences, Inc. (COGT) trailing twelve-month net income is $-354M as of 2025. Earnings declined -3.7% year-over-year.
Is COGT profitable?
COGT is not currently profitable on a TTM basis, reporting a net loss of $-354M. Net margin is N/A. Investors should monitor for a return to profitability.
What is COGT's earnings growth rate?
COGT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are COGT's profit margins?
Cogent Biosciences, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -73.7%.
Is COGT growing earnings?
COGT earnings growth is slowing. Current YoY EPS growth of -3.7% trails the 5-year CAGR of N/A. TTM net income is $-354M.
What was COGT's best earnings year?
Cogent Biosciences, Inc.'s highest annual net income on record is $-7M, achieved in fiscal year 2015. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were COGT's earnings last quarter?
COGT's most recent reported quarter was Q1 2026. Net income was $-97M with diluted EPS of $-0.60. For a full breakdown of all quarters, see the quarterly earnings table on this page.